Eye-care drugmaker Alcon said on Wednesday that the U.S. Food and Drug Administration has approved its treatment for dry eye disease (DED).

Alcon, a global eye care company known for products such as Systane and GenTeal Tears, plans to launch Tryptyr in the U.S. market in the third quarter of 2025. International rollouts are expected to ...

Six years after being spun out from Novartis and becoming a public company, eye care specialist Alcon has gained its first ...

Melbourne biotech PolyActiva says it hopes to be the next Cochlear by selling its eye drug dispensing system to millions ...

Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms ...

Alcon Inc. (NYSE:ALC) has announced that the U.S. Food and Drug Administration (FDA) has approved TRYPTYR (acoltremon ...

Dry eye syndrome, a condition affecting millions of Americans each year, continues to present a frustrating challenge for ...

Glaucoma can cause irreversible blindness and with early diagnosis and treatment key, a highly advanced new micro-stent ...

It's as if she's squinting through a smoke-filled room. But it's Charisse Brown's eye condition, glaucoma, that diminishes her vision. Brown, 38, has worked all her adult life, with a personal policy ...

A new randomized controlled trial reveals that topical timolol significantly improves the appearance of post-mammoplasty ...

The active ingredient in Tryptyr is acoltremon, an agonist of transient receptor potential melastatin 8 thermoreceptors.

As millions of Americans reach their 40s and 50s, many begin to experience the frustrating effects of presbyopia—the gradual ...